$CRDL Is Heating Up — Late-stage Biotech With Real Momentum Targeting Inflammatory Heart Disease.
https://marketwirenews.com/stock/crdl/
Cardiol Therapeutics (NASDAQ: $CRDL / TSX: CRDL) continues to execute as a late-stage company advancing anti-inflammatory and anti-fibrotic therapies for heart disease.
Key reasons the story looks compelling:
✅ Pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis: enrollment >75%, expanding U.S. network of top centers (Cleveland Clinic, Mayo, Northwestern, Mass General, and more), topline results expected in Q1 2027. Designed to support a potential NDA.
✅ Positive Phase II data: Phase II MAVERIC study showed rapid, sustained reductions in pain/inflammation and fewer recurrences with good safety; results published in Journal of the American Heart Association. ARCHER in acute myocarditis delivered meaningful LV mass reduction and cardiac improvements (published in ESC Heart Failure). ✔ Orphan Drug Designation for CardiolRx™ in pericarditis.
✅ Strong balance sheet: Runway into Q4 2027, fully funding the pivotal Phase III MAVERIC trial and pipeline milestones.
✅ Pipeline & IP: CRD-38 advancing toward IND/Phase I for heart failure; broad U.S. patent protection to late 2040.
✅ Momentum: Investor Meetings & Fireside Chats at B. Riley Mind, Muscle & Vision Summit (July 16, Boston), Canaccord Genuity’s 46th Annual Growth Conference (August 11, Boston).
✅ Recurrent pericarditis has significant unmet need. CardiolRx™ is positioned as a potential oral, non-immunosuppressive therapy earlier in the treatment pathway.
✅ With accelerating enrollment, peer-reviewed data, a strengthened board, and solid cash, Cardiol is advancing toward key value-inflection points.
https://marketwirenews.com/stock/crdl/
Cardiol Therapeutics (NASDAQ: $CRDL / TSX: CRDL) continues to execute as a late-stage company advancing anti-inflammatory and anti-fibrotic therapies for heart disease.
Key reasons the story looks compelling:
✅ Pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis: enrollment >75%, expanding U.S. network of top centers (Cleveland Clinic, Mayo, Northwestern, Mass General, and more), topline results expected in Q1 2027. Designed to support a potential NDA.
✅ Positive Phase II data: Phase II MAVERIC study showed rapid, sustained reductions in pain/inflammation and fewer recurrences with good safety; results published in Journal of the American Heart Association. ARCHER in acute myocarditis delivered meaningful LV mass reduction and cardiac improvements (published in ESC Heart Failure). ✔ Orphan Drug Designation for CardiolRx™ in pericarditis.
✅ Strong balance sheet: Runway into Q4 2027, fully funding the pivotal Phase III MAVERIC trial and pipeline milestones.
✅ Pipeline & IP: CRD-38 advancing toward IND/Phase I for heart failure; broad U.S. patent protection to late 2040.
✅ Momentum: Investor Meetings & Fireside Chats at B. Riley Mind, Muscle & Vision Summit (July 16, Boston), Canaccord Genuity’s 46th Annual Growth Conference (August 11, Boston).
✅ Recurrent pericarditis has significant unmet need. CardiolRx™ is positioned as a potential oral, non-immunosuppressive therapy earlier in the treatment pathway.
✅ With accelerating enrollment, peer-reviewed data, a strengthened board, and solid cash, Cardiol is advancing toward key value-inflection points.
